课题基金 / 基金详情

Erythropoietin in Non-Erythroid Cells: Function and Regulation

Erythropoietin in Non-Erythroid Cells: Function and Regulation
非红细胞中的促红细胞生成素:功能和调节
批准号:
8195889
负责人:
JOSEF T PRCHAL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-10-01 至 2013-09-30
关键词:
AddressAfghanistanAgingAllelesAnemiaAnimal ModelAtherosclerosisBindingBioinformaticsBiological AssayBloodBlood CirculationBlood VesselsBrainBreastCancer PatientCardiovascular DiseasesCardiovascular systemCell physiologyCellsCerebrovascular DisordersChIP-seqClinicalClinical ResearchCognitiveCongenital DisordersCrossbreedingCytomegalovirusDataDiseaseEPO geneEPOR geneElderlyElementsEmbryoEndotheliumErythrocytesErythroidErythroid CellsErythropoietinExhibitsFoundationsFutureGene Expression RegulationGene TargetingGenerationsGenesGenetic TranscriptionGenotypeGerm CellsGoalsGrant ReviewHealthHealthcareHematopoieticHematopoietic stem cellsHumanHypertensionHypoxiaHypoxia Inducible FactorHypoxia-Responsive ElementsIndividualInheritedInstitutesInstitutionInstitutional Review BoardsInterventionIntronsInvestigationIraqIschemiaKidney FailureKnock-in MouseKnockout MiceKnowledgeMalignant - descriptorMalignant NeoplasmsMembraneMethodsModelingMolecularMusMutationNervous system structureNeurologicNormal tissue morphologyOligonucleotidesOocytesOvaryPathologyPatientsPersian GulfPharmacologic SubstancePlayPolycythemiaPopulationPositioning AttributePreventionPrevention strategyPrincipal InvestigatorProductionProtocols documentationReceptor GeneRegulationRelative (related person)Renal carcinomaReporterReportingResearchRoleSignal TransductionSiteSpecificityStressStrokeTechnologyTestingTestisTherapeuticTissuesTranscriptTransgenic MiceTraumatic Brain InjuryUniversitiesUtahVariantVeteransabstractingbHLH-PAS factor HLFbasechromatin immunoprecipitationclinical effectclinically significantcognitive functionerythroid differentiationgain of functiongenome-widehigh riskhypoxia inducible factor 1improvedinstrumentinterestmouse modelnovelprogenitorprogramspromoterreceptorrecombinant human erythropoietinresponsetranscription factor

项目摘要

项目成果

JOSEF T PRCHAL的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 促红细胞生成素(Epo)是红细胞产生的主要调节剂,因为它控制红细胞的存活、增殖, 和红系祖细胞的分化。重组人Epo已被广泛用于纠正 肾衰竭贫血以及其他类型的贫血。然而,不同的临床效果,促红细胞生成素在 已经报道了在非红细胞组织中发现EPO和/或其受体(EPOR)基因的转录物, 脑、内皮、造血干细胞、乳腺、卵巢、睾丸和其他组织。报告的有益效果 包括其在中风患者缺血性脑中观察到的缺氧应激中的神经保护作用, 而其它研究表明给予Epo也可能是有害的。Epo和EpoR水平, 受HIF-1和/或HIF-2调节的细胞因子,据报道与癌症患者的存活率降低有关, 在几项临床研究和一些Epo治疗癌症的临床研究中, 患者建议给予Epo可能有害。此外,EPO和EPOR转录物已经被 在一些正常组织和许多癌症中发现。由于Epo或EpoR无效的胚胎致死性, 由于缺乏合适的动物模型,对非红细胞系细胞中Epo功能的研究一直是一个难题。 有限公司先前,我们产生了两种具有减少的Epo信号传导的可行的敲入小鼠模型(这些小鼠 贫血)和增强的Epo信号传导(这些小鼠是红细胞增多症)。这些老鼠是 用于研究非红细胞组织中的Epo功能。我们已经产生了红细胞特异性Cre表达 小鼠这些小鼠将用于恢复仅在血液中的Epo信号传导,从而拯救转基因小鼠, 贫血这些小鼠将用于在感兴趣的组织中产生功能获得性EpoR小鼠,例如 作为大脑,通过与脑特异性CRE小鼠杂交。 缺氧诱导因子(Hypoxia-inducible factors,HIF)是由缺氧诱导的关键转录因子(发现于 EPO基因调控的研究),并且在癌症中升高。HIFs是异二聚体,由一个 亚基(3种同种型; HIF-1 <$、HIF-2 <$、HIF-3 <$)和共同的b亚基。HIF-1 <$和HIF-2 <$具有显著的 同源性,并且虽然它们可以共享它们的一些靶基因的调控,但在某些情况下,它们的基因 调节是组织和基因特异性的。HIF调控的分子基础正在深入研究中。 虽然Epo是第一个被鉴定的具有用于HIF结合的确定的寡核苷酸序列的基因, EpoR基因被命名为缺氧反应元件(HRE),EpoR基因不具有保守的HRE。我们有 用染色质免疫沉淀法(ChIP)研究了HIF调控Epo转录的机制, 发现了多个促红细胞生成素基因的HRE我们的数据表明,这些HRE是差异利用HIF- 1和HIF-2的表达。基于这些证据,我们建议在选定的组织中研究HRE 在低氧和常氧条件下,使用我们机构购买的全基因组Chip-Seq仪器。 对退伍军人医疗保健的影响:老龄化的退伍军人,以及从波斯新返回的退伍军人 海湾地区,患有认知,血管和恶性疾病。从该项目获得的数据将 用于表征在一些人类恶性肿瘤中报道的增强的Epo/EpoR信号传导, 潜在的治疗性癌症靶点,而在其它情况下(即,中风)的治疗增强 Epo/EpoR在选定的组织中可能是有益的。我们正在进行的和未来计划的研究应该澄清 促红细胞生成素对动脉粥样硬化、高血压、认知功能和预防缺血诱导组织影响 损害
英文摘要
PROJECT SUMMARY/ABSTRACT Erythropoietin (Epo) is the principle regulator of red cell production, as it controls the survival, proliferation, and differentiation of erythroid progenitors. Recombinant human Epo has been widely used to correct the anemia of renal failure as well as other types of anemias. However, diverse clinical effects of Epo in nonerythroid tissues have been reported and transcripts of EPO and/or its receptor (EPOR) genes are found in brain, endothelium, hematopoietic stem cells, breast, ovary, testes, and other tissues. Reported beneficial effects of Epo include its neuroprotective role in hypoxic stress observed in the ischemic brains of stroke patients, while other studies demonstrated that Epo administration can also be detrimental. Levels of Epo and EpoR, regulated by HIF-1 and/or HIF-2, are reported to be associated with decreased survival of cancer patients and increased cancer aggressiveness in several clinical studies, and some clinical studies of Epo therapy in cancer patient suggested that Epo administration can be detrimental. Further, EPO and EPOR transcripts have been found in some normal tissues as well as in many cancers. Due to the embryonic lethality of Epo or EpoR null mice and the absence of a proper animal model, the study of Epo function in nonerythroid cells has been limited. Previously, we generated two viable knock-in mouse models with reduced Epo signaling (these mice are anemic) and with augmented Epo signaling (these mice are polycythemic). These mice are the foundation for studying Epo function in nonerythroid tissue. We have already generated erythroid-specific Cre-expressing mice. These mice will be used to restore Epo signaling only in blood, thus rescuing the transgenic mice from anemia. These mice will be used for the generation of a gain-of-function EpoR mouse in tissues of interest such as brain, by crossbreeding with brain-specific cre mice. Hypoxia-inducible factors (HIF) are the key transcription factors that are induced by hypoxia (discovered from studies of EPO gene regulation) and that are elevated in cancer. HIFs are heterodimers that consist of an ¿- subunit (3 isotypes; HIF-1¿, HIF-2¿, HIF-3¿) and a common b-subunit. HIF-1¿ and HIF-2¿ have significant homology, and while they may share regulation of some of their target genes, in some instances their gene regulation is tissue- and gene-specific. The molecular basis of HIF regulation is under intense investigation. While Epo was the first identified gene with a defined oligonucleotide sequence for HIF binding that was designated as Hypoxia Responsive Element (HRE), the EpoR gene does not have a conserved HRE. We have studied the mechanism of HIF regulation of Epo transcription using chromatin immunoprecipitation (ChIP) and have found multiple HREs of the Epo gene. Our data suggest that these HREs are differentially utilized by HIF- 1 and HIF-2 in a tissue-specific manner. Based on this evidence, we propose to study HRE in selected tissues under hypoxic and normoxic conditions using a genome-wide Chip-Seq instrument purchased by our institution. IMPACT ON VETERANS HEALTHCARE: Aging veterans, as well as newly returning veterans from Persian Gulf region, suffer from cognitive, vascular, and malignant disorders. The data obtained from this project will be used to characterize augmented Epo/EpoR signaling reported in some human malignancies and may serve as potential therapeutic cancer targets, while in other situations (i.e., strokes) the therapeutic augmentation of Epo/EpoR in selected tissues may be beneficial. Our ongoing and future planned studies should clarify the effect of Epo on atherosclerosis, hypertension, cognitive function, and prevention of ischemia-induced tissue damage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism of thrombosis in two myeloproliferative neoplasms (MPNs), polycythemia vera and essential thrombocythemia
HIF-Mediated Detrimental Consequences of Chronic Intermittent Hypoxia
HIF-Mediated Detrimental Consequences of Chronic Intermittent Hypoxia
Erythropoietin in Non-Erythroid Cells: Function and Regulation
海外基金